Utama › Kanser Paru-paru Bukan Sel Kecil › Arkansas › Little Rock
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Little Rock, AR
13 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Little Rock (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences /ID# 272923, Little Rock
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Mengambil pesertaFasa 3
- UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060), Little Rock
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Mengambil pesertaFasa 2
- CARTI Cancer Center, Little Rock
Pan-tumor MRD Study
Mengambil pesertaKajian pemerhatian
- CARTI, Little Rock
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Mengambil pesertaFasa 3
- Research Site, Little Rock
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Mengambil pesertaFasa 2
- Research Site, Little Rock
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Mengambil pesertaFasa 3
- CARTI Cancer Center ( Site 0006), Little Rock
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Mengambil pesertaFasa 3
- University of Arkansas for Medical Sciences, Little Rock
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Arkansas, Little Rock
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences, Little Rock
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences, Little Rock
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences, Little Rock
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Little Rock
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY121 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH57 kajian
- Washington, DC55 kajian
Kajian lain di Little Rock
- Skizofrenia19 kajian
- Kanser (semua jenis)14 kajian
- Gangguan Depresi Major14 kajian
- Leukemia Mieloid Akut13 kajian
- Obesiti11 kajian
- Kanser Endometrium10 kajian
- Depresi10 kajian
- Diabetes Jenis 210 kajian
- Kanser Paru-paru9 kajian
- Penyakit Kardiovaskular9 kajian
- Kanser Pundi Kencing9 kajian
- Kegagalan Jantung9 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.